Mechanisms of chemotherapy resistance in ovarian cancer

Abstract

Ovarian cancer is one of the most lethal gynecologic cancers. The standard therapy for ovarian cancer has been the same for the past two decades, a combination treatment of platinum with paclitaxel. Recently, the FDA approved three new therapeutic drugs, two poly (ADP-ribose) polymerase inhibitors (olaparib and niraparib) and one vascular endothelial growth factor inhibitor (bevacizumab) as maintenance therapies for ovarian cancer. In this review, we summarize the resistance mechanisms for conventional platinum-based chemotherapy and for the newly FDA-approved drugs.

Keywords

Drug resistance / ovarian cancer / cisplatin / carboplatin / paclitaxel / olaparib / niraparib / bevacizumab

References

[1] Siegel RL,Fuchs HE.Cancer statistics, 2021.CA Cancer J Clin2021;71:7-33

[2] Damia G.Platinum resistance in ovarian cancer: role of DNA repair.Cancers (Basel)2019;11:119 PMCID:PMC6357127

[3] Rosenberg B,Krigas T.Inhibition of cell division in escherichia coli by electrolysis products from a platinum electrode.Nature1965;205:698-9

[4] Kelland L.The resurgence of platinum-based cancer chemotherapy.Nat Rev Cancer2007;7:573-84

[5] Harrap K.Preclinical studies identifying carboplatin as a viable cisplatin alternative.Cancer Treatment Reviews1985;12:21-33

[6] Mangioni C,Pecorelli S.Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin.J Natl Cancer Inst1989;81:1464-71

[7] Weaver BA.How Taxol/paclitaxel kills cancer cells.Mol Biol Cell2014;25:2677-81 PMCID:PMC4161504

[8] Parmar MK,Colombo N.Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.Lancet2003;361:2099-106

[9] Dasari S.Cisplatin in cancer therapy: molecular mechanisms of action.Eur J Pharmacol2014;740:364-78 PMCID:PMC4146684

[10] Gottesman MM,Bates SE.Multidrug resistance in cancer: role of ATP-dependent transporters.Nat Rev Cancer2002;2:48-58

[11] Gottesman MM.Mechanisms of cancer drug resistance.Annu Rev Med2002;53:615-27

[12] Gillet J.Mechanisms of multidrug resistance in cancer. in: zhou j, editor.Multi-drug resistance in cancer.2010. p. 47-76

[13] Robey RW,Hall MD.Revisiting the role of ABC transporters in multidrug-resistant cancer.Nat Rev Cancer2018;18:452-64 PMCID:PMC6622180

[14] Kalayda GV,Jaehde U.Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells.J Inorg Biochem2012;116:1-10

[15] Holzer AK,Katano K.The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells.Mol Pharmacol2004;66:817-23

[16] Ishida S,Smith-McCune K.Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator.Cancer Cell2010;17:574-83 PMCID:PMC2902369

[17] Holzer AK,Klomp LW.Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells.Clin Cancer Res2004;10:6744-9

[18] Kilari D,Kim ES.Role of copper transporters in platinum resistance.World J Clin Oncol2016;7:106-13 PMCID:PMC4734932

[19] Samimi G,Katano K.Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells.Clin Cancer Res2004;10:4661-9

[20] Safaei R,Larson BJ,Howell SB.Transport of cisplatin by the copper efflux transporter ATP7B.Mol Pharmacol2008;73:461-8

[21] Mangala LS,Schmandt R.Therapeutic targeting of ATP7B in ovarian carcinoma.Clin Cancer Res2009;15:3770-80 PMCID:PMC2752981

[22] Nakayama K,Ogawa K,Neamati N.Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP.Int J Cancer2002;101:488-95

[23] Nakayama K,Terada K.Prognostic value of the Cu-transporting ATPase in ovarian carcinoma patients receiving cisplatin-based chemotherapy.Clin Cancer Res2004;10:2804-11

[24] Li T,Zeng F.Association between polymorphisms in CTR1, CTR2, ATP7A, and ATP7B and platinum resistance in epithelial ovarian cancer.Int J Clin Pharmacol Ther2017;55:774-80

[25] Colombo PE,Theillet C,Rouanet P.Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer.Crit Rev Oncol Hematol2014;89:207-16

[26] Du P,Chen L,Wu Q.High ERCC1 expression is associated with platinum-resistance, but not survival in patients with epithelial ovarian cancer.Oncol Lett2016;12:857-62

[27] Plumb JA,Sludden J,Brown R.Reversal of drug resistance in human tumor xenografts by 2’-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.Cancer Res2000;60:6039-44

[28] Li GM.Mechanisms and functions of DNA mismatch repair.Cell Res2008;18:85-98

[29] Shen J,Chen L.Ubiquitin-specific protease 14 regulates ovarian cancer cisplatin-resistance by stabilizing BCL6 oncoprotein.Biochem Biophys Res Commun2020;524:683-8

[30] Zhou F,Zhao H.Down-regulation of OGT promotes cisplatin resistance by inducing autophagy in ovarian cancer.Theranostics2018;8:5200-12 PMCID:PMC6276088

[31] Shen L,Xia M.PGC1α regulates mitochondrial oxidative phosphorylation involved in cisplatin resistance in ovarian cancer cells via nucleo-mitochondrial transcriptional feedback.Exp Cell Res2021;398:112369

[32] Hanahan D.Hallmarks of cancer: new dimensions.Cancer Discov2022;12:31-46

[33] Sun H,Wang X.Aurora-A/SOX8/FOXK1 signaling axis promotes chemoresistance via suppression of cell senescence and induction of glucose metabolism in ovarian cancer organoids and cells.Theranostics2020;10:6928-45 PMCID:PMC7295065

[34] Wang Z,Zuo L.The fibrillin-1/VEGFR2/STAT2 signaling axis promotes chemoresistance via modulating glycolysis and angiogenesis in ovarian cancer organoids and cells.Cancer Commun (Lond)2022;42:245-65 PMCID:PMC8923131

[35] Orr GA,McDaid H.Mechanisms of Taxol resistance related to microtubules.Oncogene2003;22:7280-95 PMCID:PMC4039039

[36] Kops GJ,Cleveland DW.On the road to cancer: aneuploidy and the mitotic checkpoint.Nat Rev Cancer2005;5:773-85

[37] Jang SH,Au JL.Kinetics of P-glycoprotein-mediated efflux of paclitaxel.J Pharmacol Exp Ther2001;298:1236-42

[38] Vahedi S,Ambudkar SV.Global alteration of the drug-binding pocket of human P-glycoprotein (ABCB1) by substitution of fifteen conserved residues reveals a negative correlation between substrate size and transport efficiency.Biochem Pharmacol2017;143:53-64 PMCID:PMC5610938

[39] Sajid A,Murakami M.Reversing the direction of drug transport mediated by the human multidrug transporter P-glycoprotein.Proc Natl Acad Sci U S A2020;117:29609-17 PMCID:PMC7703596

[40] Maloney SM,Morejon-Lasso LV.Mechanisms of taxane resistance.Cancers (Basel)2020;12:3323 PMCID:PMC7697134

[41] Kavallaris M,Burkhart CA.Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.J Clin Invest1997;100:1282-93 PMCID:PMC508306

[42] Feng Q,Sun W.Targeting G6PD reverses paclitaxel resistance in ovarian cancer by suppressing GSTP1.Biochem Pharmacol2020;178:114092

[43] Sawers L,Ihrig BR.Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines.Br J Cancer2014;111:1150-8 PMCID:PMC4453841

[44] Whitaker RH.Regulating the BCL2 family to improve sensitivity to microtubule targeting agents.Cells2019;8:346 PMCID:PMC6523793

[45] Haldar S,Croce CM.Taxol induces bcl-2 phosphorylation and death of prostate cancer cells.Cancer Res1996;56:1253-5

[46] Ferlini C,Raspaglio G.Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77.Cancer Res2009;69:6906-14

[47] Lin B,Lin F.Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3.Cell2004;116:527-40

[48] Srivastava RK,Hardwick JM.Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription.J Exp Med1999;190:253-65 PMCID:PMC2195578

[49] Ben-Hamo R,Cohen H.Resistance to paclitaxel is associated with a variant of the gene BCL2 in multiple tumor types.NPJ Precis Oncol2019;3:12 PMCID:PMC6478919

[50] Patel RP,Yin D.Cross-resistance of cisplatin selected cells to anti-microtubule agents: role of general survival mechanisms.Transl Oncol2021;14:100917 PMCID:PMC7586247

[51] Taylor KN.PARP Inhibitors in epithelial ovarian cancer.Recent Pat Anticancer Drug Discov2018;13:145-58

[52] Murai J,Das BB.Trapping of PARP1 and PARP2 by clinical PARP inhibitors.Cancer Res2012;72:5588-99 PMCID:PMC3528345

[53] Klotz DM.Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?.Arch Gynecol Obstet2020;302:1087-102 PMCID:PMC7524817

[54] Lord CJ.PARP inhibitors: synthetic lethality in the clinic.Science2017;355:1152-8 PMCID:PMC6175050

[55] Jiang X,Li W,Zhang Z.PARP inhibitors in ovarian cancer: sensitivity prediction and resistance mechanisms.J Cell Mol Med2019;23:2303-13 PMCID:PMC6433712

[56] Vescarelli E,Megiorni F.MiR-200c sensitizes olaparib-resistant ovarian cancer cells by targeting neuropilin 1.J Exp Clin Cancer Res2020;39:3 PMCID:PMC6939329

[57] Liu L,Han C.ALDH1A1 contributes to PARP inhibitor resistance via enhancing DNA repair in BRCA2^-/- ovarian cancer cells.Mol Cancer Ther2020;19:199-210 PMCID:PMC6946874

[58] Watson ZL,McMellen A.Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma.Clin Epigenetics2019;11:165 PMCID:PMC6882350

[59] Yamamoto TM,Watson ZL.Activation of wnt signaling promotes olaparib resistant ovarian cancer.Mol Carcinog2019;58:1770-82 PMCID:PMC7537108

[60] Hustedt N.The control of DNA repair by the cell cycle.Nat Cell Biol2016;19:1-9

[61] Kastan MB.Cell-cycle checkpoints and cancer.Nature2004;432:316-23

[62] Brill E,Nair J,Ahn YR.Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases.in vitro8:111026-40 PMCID:PMC5762302

[63] Nair J,Murai J.Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer.Oncogene2020;39:5520-35 PMCID:PMC7426265

[64] MacQueen AJ.Catching a (Double-Strand) Break: the Rad51 and Dmc1 strand exchange proteins can co-occupy both ends of a meiotic DNA double-strand break.PLoS Genet2015;11:e1005741 PMCID:PMC4699915

[65] Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma.Nature2011;474:609-15

[66] Vaidyanathan A,Gannon AL.ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells.Br J Cancer2016;115:431-41 PMCID:PMC4985349

[67] Mirza MR,Herrstedt J.ENGOT-OV16/NOVA investigatorsniraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer.N Engl J Med2016;375:2154-64

[68] Santiago-O'Farrill JM,Hou X.Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models.Cancer2020;126:894-907 PMCID:PMC6992526

[69] Kazazi-Hyseni F,Schellens JH.Bevacizumab.Oncologist2010;15:819-25 PMCID:PMC3228024

[70] Carmeliet P.VEGF as a key mediator of angiogenesis in cancer.Oncology2005;69 Suppl 3:4-10

[71] Mancuso MR,Norberg SM.Rapid vascular regrowth in tumors after reversal of VEGF inhibition.J Clin Invest2006;116:2610-21 PMCID:PMC1578604

[72] Itatani Y,Yamamoto T.Resistance to anti-angiogenic therapy in cancer-alterations to anti-VEGF pathway.Int J Mol Sci2018;19:1232 PMCID:PMC5979390

[73] Haibe Y,El Hajj H.Resistance mechanisms to anti-angiogenic therapies in cancer.Front Oncol2020;10:221 PMCID:PMC7056882

[74] Arjaans M,Oosting SF.Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake.Cancer Res2013;73:3347-55

[75] Pinto MP,Carrasco-Avino G,Owen GI.Escaping antiangiogenic therapy: strategies employed by cancer cells.Int J Mol Sci2016;17:1489 PMCID:PMC5037767

[76] Franco M,Cortez E,Pietras K.Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression.Blood2011;118:2906-17 PMCID:PMC3172806

[77] Guerrouahen BS,Kaoud NA.Akt-activated endothelium constitutes the niche for residual disease and resistance to bevacizumab in ovarian cancer.Mol Cancer Ther2014;13:3123-36

[78] Erber R,Powajbo V.EphB4 controls blood vascular morphogenesis during postnatal angiogenesis.EMBO J2006;25:628-41 PMCID:PMC1383533

[79] Li L,Guo Q,Zhou C.Resistance to bevacizumab in ovarian cancer SKOV3 xenograft due to EphB4 overexpression.J Cancer Res Ther2019;15:1282-7

[80] Mohammad IS,Yin L.Insight on multidrug resistance and nanomedicine approaches to overcome MDR.Crit Rev Ther Drug Carrier Syst2020;37:s473-509